← Back to Search
Other
AFA-281 for Alcoholism
Los Angeles, CA
Phase 2
Waitlist Available
Led By Lara Ray, MD
Research Sponsored by Afasci Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age between 21 and 65
Report drinking at least 28 drinks per week if male, 21 drinks per week if female, in the 28 days prior to consent
Must not have
Has an estimated creatinine clearance (CrCl) outside of normal range
Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab). Negative HIV status will be confirmed at Screening and the results will be maintained confidentially by the study site
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose and weekly through week 4
Summary
"This trial will look at whether AFA-281 is safe and effective in reducing cravings and improving various symptoms in patients with Alcohol use disorder."
See full description
Who is the study for?
This trial is for individuals with Alcohol Use Disorder who may also experience sleep issues, depression, anxiety, or altered pain tolerance. Specific eligibility details are not provided but typically include age range, health status, and severity of alcoholism.Check my eligibility
What is being tested?
The study tests the safety and potential effectiveness of a new oral medication called AFA-281 on reducing cravings for alcohol and improving related conditions like pain sensitivity, mood disorders (anxiety/depression), and sleep disturbances.See study design
What are the potential side effects?
While specific side effects are not listed here, common ones for medications treating similar conditions can include nausea, dizziness, headache, fatigue or changes in appetite. Patients will be monitored closely for any adverse reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 21 and 65 years old.
show original
Select...
I have been drinking more than 28 (if male) or 21 (if female) alcoholic drinks weekly for the last month.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My kidney function, measured by creatinine clearance, is not normal.
show original
Select...
I have tested positive for hepatitis A, B, C, or HIV.
show original
Select...
I have fainted or almost fainted when standing up quickly.
show original
Select...
I am currently diagnosed with major depression and have thoughts of suicide.
show original
Select...
I do not have any major health issues like heart, lung (except mild asthma), kidney, liver, stomach, blood, hormone-related conditions, skin problems, metabolic diseases, or severe mental health issues.
show original
Select...
I have had a head injury that caused me to lose consciousness or have seizures.
show original
Select...
I have had surgery on my stomach or intestines that could affect digestion.
show original
Select...
I haven't donated or lost significant blood or received a transfusion in the last 8 weeks.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ predose and weekly through week 4
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose and weekly through week 4
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Cue-induced alcohol craving
Pain assessments
Safety and tolerability assessment
+2 moreSecondary study objectives
Daily diary report
Trial Design
3Treatment groups
Active Control
Placebo Group
Group I: Low dose of AFA-281Active Control1 Intervention
AFA-281 at 60 mg per day
Group II: High dose AFA-281Active Control1 Intervention
AFA-281 at 120 mg per day
Group III: AFA-281 placebo controlPlacebo Group1 Intervention
AFA-281 placebo control group
Find a Location
Closest Location:University of California· Los Angeles, CA· 1170 miles
Who is running the clinical trial?
Afasci IncLead Sponsor
3 Previous Clinical Trials
450 Total Patients Enrolled
Lara Ray, MDPrincipal InvestigatorUniversity of California, Los Angeles